CLEANNA
6.3.2024 11:01:34 CET | Business Wire | Press release
CleanNA, a Dutch manufacturer of magnetic bead-based nucleic acid extraction kits and systems, launched its second CE-IVD marked product. The company’s Clean Quick Viral DNA/RNA (CE-IVD) extracts viral DNA and RNA from nasopharyngeal or oropharyngeal swab samples preserved in an inactivating viral transport medium. Clean Quick Viral DNA/RNA is based on magnetic beads, which makes the protocol easy to automate on CleanNA’s CleanXtract 96 or general liquid handlers. Extracted DNA and RNA is directly suitable for downstream applications based on (q)PCR.
If we learned one thing from the COVID 19 pandemic, it is the fact that the world requires quick and dependable methods for identifying pathogens. Timely detection of emerging pathogens allows for the implementation of suitable preventive measures. Moreover, in the case of an infected patient, prompt identification of the pathogen is crucial to deliver the correct treatment. Clean Quick Viral DNA/RNA serves as an ideal starting point for virus identification workflows.
CleanNA developed the Clean Quick Viral DNA/RNA for use in diagnostic workflows, that is why the product is CE-IVD marked. The In Vitro Diagnostic Regulations of the European Union have the goal to ensure that products are safe, effective and reliable and they apply to all in vitro diagnostic medical devices on the EU market.
“Clean Quick Viral DNA/RNA is the next CE-IVD marked product we launch in a short period of time. The unique aspect of this reagent is that it works on our CleanXtract 96, making it possible to automate the process for viral DNA and RNA extraction in diagnostics.”
– Glenn Nohar, CEO of CleanNA
Launch of the Clean Quick Viral DNA/RNA (CE-IVD) follows quickly after the introduction of the Clean Cell Free DNA Kit (CE-IVD) last November. This shows that CleanNA is focused on the molecular diagnostics market. The company plans to launch more CE-IVD kits the coming year.
About CleanNA:
CleanNA is a Dutch manufacturer of nucleic acid extraction kits and systems that are based on an easy bind-wash-elute principle using magnetic beads. Their quality management system is EN-ISO 13485 certified by Bureau Veritas. The company’s product portfolio exists nucleic acid extraction and cleanup kits for both RUO and diagnostic procedures. Due to the use of magnetic beads, the products are ideally suited for use in automated extraction procedures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306688682/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom